CORONA, Calif., March 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that, under a supply agreement with Procter & Gamble Pharmaceuticals, the Company has initiated shipments of nitrofurantoin monohydrate/macrocrystals capsules, the authorized generic version of Procter & Gamble's Macrobid(R).
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Macrobid(R) is indicated for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. For the 12-months ending January 2004, Macrobid(R) had U.S. sales of approximately $158 million, according to IMS Health data. Procter & Gamble will receive a share of the profits from Watson's sales of the authorized generic nitrofurantoin monohydrate/macrocrystals capsules in the US market. Terms of the agreement have not been disclosed.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/ .
Forward-Looking Statement
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing, market acceptance of and demand for Watson's products, and risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2003.
Macrobid(R) is a registered trademark of Procter & Gamble Pharmaceuticals.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.CONTACT: investors, Patty Eisenhaur, +1-909-493-5611, or media, ChrisEso, +1-909-493-4013, both of Watson Pharmaceuticals, Inc.
Web site: http://www.watsonpharm.com/
